Status:
COMPLETED
S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313
Lead Sponsor:
SWOG Cancer Research Network
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
RATIONALE: Studying the proteins expressed in tumor tissue samples in the laboratory from patients with cancer may help doctors learn more about biomarkers related to cancer. It may also help doctors ...
Detailed Description
OBJECTIVES: * Assess in-situ protein expression of estrogen receptor (ER), progesterone receptor (PR), HER-2, and p53 by automated quantitative analysis (AQUA™) and multiplexed analysis at 2 markers ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of primary invasive adenocarcinoma of the breast
- Stage I-IIIA disease (T1-3, N0-1, M0)
- Enrolled on clinical trial SWOG-9313
- Tumor tissue available for testing
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
July 17 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 2 2009
Estimated Enrollment :
2100 Patients enrolled
Trial Details
Trial ID
NCT00896727
Start Date
July 17 2006
End Date
April 2 2009
Last Update
December 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Cancer Center
New Haven, Connecticut, United States, 06520-8028